ArticleClinical pharmacology in drug development2022

Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors.

Xiaofei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.